These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34995458)

  • 1. Design, Synthesis, and Characterization of I-BET567, a Pan-Bromodomain and Extra Terminal (BET) Bromodomain Oral Candidate.
    Humphreys PG; Atkinson SJ; Bamborough P; Bit RA; Chung CW; Craggs PD; Cutler L; Davis R; Ferrie A; Gong G; Gordon LJ; Gray M; Harrison LA; Hayhow TG; Haynes A; Henley N; Hirst DJ; Holyer ID; Lindon MJ; Lovatt C; Lugo D; McCleary S; Molnar J; Osmani Q; Patten C; Preston A; Rioja I; Seal JT; Smithers N; Sun F; Tang D; Taylor S; Theodoulou NH; Thomas C; Watson RJ; Wellaway CR; Zhu L; Tomkinson NCO; Prinjha RK
    J Med Chem; 2022 Feb; 65(3):2262-2287. PubMed ID: 34995458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure- and Property-Based Optimization of Efficient Pan-Bromodomain and Extra Terminal Inhibitors to Identify Oral and Intravenous Candidate I-BET787.
    Hirst DJ; Bamborough P; Al-Mahdi N; Angell DC; Barnett HA; Baxter A; Bit RA; Brown JA; Chung CW; Craggs PD; Davis RP; Demont EH; Ferrie A; Gordon LJ; Harada I; Ho TCT; Holyer ID; Hooper-Greenhill E; Jones KL; Lindon MJ; Lovatt C; Lugo D; Maller C; McGonagle G; Messenger C; Mitchell DJ; Pascoe DD; Patel VK; Patten C; Poole DL; Shah RR; Rioja I; Stafford KAJ; Tape D; Taylor S; Theodoulou NH; Tomlinson L; Wall ID; Wellaway CR; White G; Prinjha RK; Humphreys PG
    J Med Chem; 2024 Jun; 67(12):10464-10489. PubMed ID: 38866424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Optimization of a Ligand-Efficient Benzoazepinone Bromodomain and Extra Terminal (BET) Family Acetyl-Lysine Mimetic into the Oral Candidate Quality Molecule I-BET432.
    Humphreys PG; Anderson NA; Bamborough P; Baxter A; Chung CW; Cookson R; Craggs PD; Dalton T; Fournier JCL; Gordon LJ; Gray HF; Gray MW; Gregory R; Hirst DJ; Jamieson C; Jones KL; Kessedjian H; Lugo D; McGonagle G; Patel VK; Patten C; Poole DL; Prinjha RK; Ramirez-Molina C; Rioja I; Seal G; Stafford KAJ; Shah RR; Tape D; Theodoulou NH; Tomlinson L; Ukuser S; Wall ID; Wellaway N; White G
    J Med Chem; 2022 Nov; 65(22):15174-15207. PubMed ID: 36378954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 4-phenylisoquinolinone BET bromodomain inhibitors.
    Bennett MJ; Wu Y; Boloor A; Matuszkiewicz J; O'Connell SM; Shi L; Stansfield RK; Del Rosario JR; Veal JM; Hosfield DJ; Xu J; Kaldor SW; Stafford JA; Betancort JM
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1811-1816. PubMed ID: 29657099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and Synthesis of a Highly Selective and
    Preston A; Atkinson S; Bamborough P; Chung CW; Craggs PD; Gordon L; Grandi P; Gray JRJ; Jones EJ; Lindon M; Michon AM; Mitchell DJ; Prinjha RK; Rianjongdee F; Rioja I; Seal J; Taylor S; Wall I; Watson RJ; Woolven J; Demont EH
    J Med Chem; 2020 Sep; 63(17):9070-9092. PubMed ID: 32691591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor.
    Gosmini R; Nguyen VL; Toum J; Simon C; Brusq JM; Krysa G; Mirguet O; Riou-Eymard AM; Boursier EV; Trottet L; Bamborough P; Clark H; Chung CW; Cutler L; Demont EH; Kaur R; Lewis AJ; Schilling MB; Soden PE; Taylor S; Walker AL; Walker MD; Prinjha RK; Nicodème E
    J Med Chem; 2014 Oct; 57(19):8111-31. PubMed ID: 25249180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.
    Chan KH; Zengerle M; Testa A; Ciulli A
    J Med Chem; 2018 Jan; 61(2):504-513. PubMed ID: 28595007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GSK789: A Selective Inhibitor of the First Bromodomains (BD1) of the Bromo and Extra Terminal Domain (BET) Proteins.
    Watson RJ; Bamborough P; Barnett H; Chung CW; Davis R; Gordon L; Grandi P; Petretich M; Phillipou A; Prinjha RK; Rioja I; Soden P; Werner T; Demont EH
    J Med Chem; 2020 Sep; 63(17):9045-9069. PubMed ID: 32691589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Benzo[
    Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
    J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.
    Seal JT; Atkinson SJ; Aylott H; Bamborough P; Chung CW; Copley RCB; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Lindon M; Messenger C; Michon AM; Mitchell D; Preston A; Prinjha RK; Rioja I; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
    J Med Chem; 2020 Sep; 63(17):9093-9126. PubMed ID: 32702236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.
    Pearson AD; DuBois SG; Buenger V; Kieran M; Stegmaier K; Bandopadhayay P; Bennett K; Bourdeaut F; Brown PA; Chesler L; Clymer J; Fox E; French CA; Germovsek E; Giles FJ; Bender JG; Hattersley MM; Ludwinski D; Luptakova K; Maris J; McDonough J; Nikolova Z; Smith M; Tsiatis AC; Vibhakar R; Weiner S; Yi JS; Zheng F; Vassal G
    Eur J Cancer; 2021 Mar; 146():115-124. PubMed ID: 33601323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.
    Law RP; Atkinson SJ; Bamborough P; Chung CW; Demont EH; Gordon LJ; Lindon M; Prinjha RK; Watson AJB; Hirst DJ
    J Med Chem; 2018 May; 61(10):4317-4334. PubMed ID: 29656650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel phenanthridin-6(5H)-one derivatives as potent and selective BET bromodomain inhibitors: Rational design, synthesis and biological evaluation.
    Zhi Y; Wang S; Huang W; Zeng S; Liang M; Zhang C; Ma Z; Wang Z; Zhang Z; Shen Z
    Eur J Med Chem; 2019 Oct; 179():502-514. PubMed ID: 31276895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a potent, orally available furopyridine derivative as a novel selective bromodomain and extra-terminal domain (BET)-first bromodomain (BD1) inhibitor.
    Hagihara S; Ishizawa K; Kikuchi M; Kawano Y; Nishidate A; Matsumoto F; Hashimoto N; Sasaki C; Miyaguchi I; Okada O; Akashi T; Nakayama S; Ogasawara Y; Endo J
    Bioorg Med Chem Lett; 2024 Sep; 109():129848. PubMed ID: 38876176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.
    McDaniel KF; Wang L; Soltwedel T; Fidanze SD; Hasvold LA; Liu D; Mantei RA; Pratt JK; Sheppard GS; Bui MH; Faivre EJ; Huang X; Li L; Lin X; Wang R; Warder SE; Wilcox D; Albert DH; Magoc TJ; Rajaraman G; Park CH; Hutchins CW; Shen JJ; Edalji RP; Sun CC; Martin R; Gao W; Wong S; Fang G; Elmore SW; Shen Y; Kati WM
    J Med Chem; 2017 Oct; 60(20):8369-8384. PubMed ID: 28949521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.
    Zhao Y; Zhou B; Bai L; Liu L; Yang CY; Meagher JL; Stuckey JA; McEachern D; Przybranowski S; Wang M; Ran X; Aguilar A; Hu Y; Kampf JW; Li X; Zhao T; Li S; Wen B; Sun D; Wang S
    J Med Chem; 2018 Jul; 61(14):6110-6120. PubMed ID: 30015487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fragment-Based, Structure-Enabled Discovery of Novel Pyridones and Pyridone Macrocycles as Potent Bromodomain and Extra-Terminal Domain (BET) Family Bromodomain Inhibitors.
    Wang L; Pratt JK; Soltwedel T; Sheppard GS; Fidanze SD; Liu D; Hasvold LA; Mantei RA; Holms JH; McClellan WJ; Wendt MD; Wada C; Frey R; Hansen TM; Hubbard R; Park CH; Li L; Magoc TJ; Albert DH; Lin X; Warder SE; Kovar P; Huang X; Wilcox D; Wang R; Rajaraman G; Petros AM; Hutchins CW; Panchal SC; Sun C; Elmore SW; Shen Y; Kati WM; McDaniel KF
    J Med Chem; 2017 May; 60(9):3828-3850. PubMed ID: 28368119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of Benzo[cd]indol-2(1H)-ones as Potent and Specific BET Bromodomain Inhibitors: Structure-Based Virtual Screening, Optimization, and Biological Evaluation.
    Xue X; Zhang Y; Liu Z; Song M; Xing Y; Xiang Q; Wang Z; Tu Z; Zhou Y; Ding K; Xu Y
    J Med Chem; 2016 Feb; 59(4):1565-79. PubMed ID: 26731490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of ZA channel water-mediated interactions in the design of bromodomain-selective BET inhibitors.
    Bharatham N; Slavish PJ; Shadrick WR; Young BM; Shelat AA
    J Mol Graph Model; 2018 May; 81():197-210. PubMed ID: 29605436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer.
    Xue X; Zhang Y; Wang C; Zhang M; Xiang Q; Wang J; Wang A; Li C; Zhang C; Zou L; Wang R; Wu S; Lu Y; Chen H; Ding K; Li G; Xu Y
    Eur J Med Chem; 2018 May; 152():542-559. PubMed ID: 29758518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.